

JOHNSON

PHARMACARE LIMITED

(Formerly Known as SUN AND SHINE WORLDWIDE LIMITED)

CIN: L51100GJ1994PLC022388

Registered Office Address -Regus, 1101-1106, Earth Arise, 11th Floor
Sarkhej Gandhinagar Highway, Makarba
Ahmedabad, Gujarat, India - 380015

E-Mail:sunandshineworldwidelttd@gmail.com

Date: 10.08.2023

To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Dear Sir / Madam,

Sub: Un-Audited Financial Result quarter ending 30th June, 2023 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. **Thursday 10th August 2023** at the Registered Office of the Company and transacted the following major businesses:

1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June, 2023.

The board meeting concluded on 06.30 P.M.

Please take the above intimation in your records

Thanking You,

Yours Faithfully,
FOR, JOHNSON PHARMACARE LIMITED

DIRECTOR / AUTHORIZED SIGNATORY



Johnson Pharmacare Limited

Formerly Known as Sun and Shine Worldwide Limited

CIN:- L51100GJ1994PLC022388

Regd. Office: Regus, 1101-1106, Earth Arise, 11th Floor, Sarkhej Gandhinagar Highway, Makarba, Ahmedabad - 380015

Email - sunandshineworldwideltd@gmail.com

Statement of Unaudited Financial Results for the Quarter Ended June 30, 2023

(Rs. In lacs)

Sl no.	Particulars	Quarter Ended 30 June 2023	Quarter Ended 31st March 2023	Quarter Ended 30 June 2022	Year Ended 31 Mar 2023
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	REVENUE FROM OPERATIONS				
(a)	Income from Operations			252.68	252.68
(b)	Other Income				11.91
(c)	Other Income			270.00	100.00
2	EXPENSES				
(a)	Cost of Materials consumed				10.00
(b)	Salaries, wages, honoraries, and such other emoluments payable to employees				10.00
(c)	Depreciation and amortisation expense				10.00
(d)	Finance Costs				10.00
(e)	Depreciation and amortisation expense				10.00
(f)	Other expenses	10.00	10.00		10.00
(g)	Other expenses	10.00	10.00	10.00	10.00
(h)	Profit Before Exceptional Items and Tax	10.00	10.00	10.00	10.00
(i)	Exceptional Items				

Approved on behalf of the Board

Signature of the Director/Authorized Signatory

Signature of the Director/Authorized Signatory

Signature of the Director/Authorized Signatory

Signature of the Director/Authorized Signatory

Signature of the Director/Authorized Signatory

Signature of the Director/Authorized Signatory

Signature of the Director/Authorized Signatory


Signature of the Director/Authorized Signatory

Signature of the Director/Authorized Signatory

Signature of the Director/Authorized Signatory

Signature of the Director/Authorized Signatory

Signature of the Director/Authorized Signatory



GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.
Tel.: 9820501848 Email : rishisekhri@gmail.com

Limited Review Report on unaudited standalone financial results of Johnson Pharmacare Ltd for the quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Johnson Pharmacare Ltd

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Johnson Pharmicare Ltd for the quarter ended 30 June 2023 ("the Statement"), being submitted pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires the reviewer and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and is substantially less than the audit conducted in accordance with the standards on Auditing Specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards i.e. Ind AS 34 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.